文献速递慢阻肺呼吸道感染

重组烟曲霉过敏原致敏与慢阻肺临床结局

Sensitisation to recombinant Aspergillus fumigatus allergens and clinical outcomes in COPD.
PubMed 文献 · Eur Respir J · 2023-01-06

在三国五中心前瞻性评估614例稳定期慢阻肺患者,检测35种真菌过敏原(含粗提与重组烟曲霉过敏原)。烟曲霉致敏与急性加重增加相关,仅对重组烟曲霉过敏原f1、3、5、6致敏者亦呈现加重增多、肺功能更差及预后更差。

要点

  • 烟曲霉致敏是慢阻肺可治疗特质,与急性加重增加相关。
  • 仅对重组烟曲霉过敏原致敏的患者预后更差,易被粗提过敏原检测遗漏。
  • 枝孢霉致敏组症状更明显,但与加重增加无明确关联。

核心结论

  • 烟曲霉致敏是慢阻肺可治疗特质。
  • 检测重组烟曲霉过敏原可识别仅对重组过敏原致敏且结局差的患者亚组,该亚组被仅用粗提过敏原评估所遗漏。

研究设计与样本

  • 前瞻性多中心评估稳定期慢阻肺患者614例,来自新加坡、马来西亚和中国香港共五家医院。
  • 对35种真菌过敏原(含粗提与重组烟曲霉及非烟曲霉过敏原)进行临床与血清学评估,采用无监督聚类和拓扑数据分析(TDA)。

主要发现

  • 烟曲霉致敏与慢阻肺急性加重增加相关。
  • 无监督聚类分析发现两个真菌致敏组:第一组以烟曲霉致敏为特征,急性加重增多、肺功能更差、预后更差,多重致敏者结局更差;第二组以枝孢霉致敏为特征,症状更明显。
  • 相当数量个体仅对重组烟曲霉过敏原f1、3、5、6致敏,表现为急性加重增多、肺功能更差和总体预后更差。
  • TDA验证上述发现,并额外识别烟曲霉致敏慢阻肺中频繁急性加重的亚组。

临床怎么用

  • 在慢阻肺评估中关注烟曲霉致敏,可将其视为可治疗特质。
  • 检测重组烟曲霉过敏原f1、3、5、6有助于识别仅用粗提过敏原检测遗漏的高风险患者亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Variable clinical outcomes are reported with fungal sensitisation in chronic obstructive pulmonary disease (COPD), and it remains unclear which fungi and what allergens associate with the poorest outcomes. The use of recombinant as opposed to crude allergens for such assessment is unknown. METHODS: A prospective multicentre assessment of stable COPD (n=614) was undertaken in five hospitals across three countries: Singapore, Malaysia and Hong Kong. Clinical and serological assessment was performed against a panel of 35 fungal allergens including crude and recombinant Aspergillus and non-Aspergillus allergens. Unsupervised clustering and topological data analysis (TDA) approaches were employed using the measured sensitisation responses to elucidate if sensitisation subgroups exist and their related clinical outcomes. RESULTS: Aspergillus fumigatus sensitisation was associated with increased exacerbations in COPD. Unsupervised cluster analyses revealed two "fungal sensitisation" groups. The first was characterised by Aspergillus sensitisation and increased exacerbations, poorer lung function and worse prognosis. Polysensitisation in this group conferred even poorer outcome. The second group, characterised by Cladosporium sensitisation, was more symptomatic. Significant numbers of individuals demonstrated sensitisation responses to only recombinant (as opposed to crude) A. fumigatus allergens f 1, 3, 5 and 6, and exhibited increased exacerbations, poorer lung function and an overall worse prognosis. TDA validated these findings and additionally identified a subgroup within Aspergillus-sensitised COPD of patients with frequent exacerbations. CONCLUSION: Aspergillus sensitisation is a treatable trait in COPD. Measuring sensitisation responses to recombinant Aspergillus allergens identifies an important patient subgroup with poor COPD outcomes that remains overlooked by assessment of only crude Aspergillus allergens.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Tiew PY, Narayana JK, Quek MSL, et al. Sensitisation to recombinant Aspergillus fumigatus allergens and clinical outcomes in COPD. Eur Respir J. 2023. PMID: 35926878. doi:10.1183/13993003.00507-2022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。